H.C. Wainwright Reaffirms Buy Rating on Eton Pharmaceuticals (ETON) Amid Raised Guidance
H.C. Wainwright upgraded its price target for Eton Pharmaceuticals to $57 from $52 and maintained a 'Buy' rating, citing strong Q1 2026 results and raised full-year revenue guidance. The company reported product sales of $24.3 million in the quarter, up 73% year-over-year.
Tickers: $ETON
Topics: Earnings FDA Approval Pharmaceuticals Revenue Guidance